602 related articles for article (PubMed ID: 27487144)
1. Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer.
Wadosky KM; Koochekpour S
Oncotarget; 2016 Sep; 7(39):64447-64470. PubMed ID: 27487144
[TBL] [Abstract][Full Text] [Related]
2. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
Karantanos T; Evans CP; Tombal B; Thompson TC; Montironi R; Isaacs WB
Eur Urol; 2015 Mar; 67(3):470-9. PubMed ID: 25306226
[TBL] [Abstract][Full Text] [Related]
3. Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer.
Guo C; Yeh S; Niu Y; Li G; Zheng J; Li L; Chang C
Cancer Lett; 2017 Jul; 397():133-143. PubMed ID: 28323036
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
5. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
6. Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer.
Annala M; Struss WJ; Warner EW; Beja K; Vandekerkhove G; Wong A; Khalaf D; Seppälä IL; So A; Lo G; Aggarwal R; Small EJ; Nykter M; Gleave ME; Chi KN; Wyatt AW
Eur Urol; 2017 Jul; 72(1):34-42. PubMed ID: 28259476
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA Regulation of Androgen Receptor in Castration-Resistant Prostate Cancer: Premises, Promises, and Potentials.
Ebrahimi S; Hashemy SI; Sahebkar A; Aghaee Bakhtiari SH
Curr Mol Pharmacol; 2021 Oct; 14(4):559-569. PubMed ID: 33357209
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence.
Coutinho I; Day TK; Tilley WD; Selth LA
Endocr Relat Cancer; 2016 Dec; 23(12):T179-T197. PubMed ID: 27799360
[TBL] [Abstract][Full Text] [Related]
9. Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer.
Loriot Y; Eymard JC; Patrikidou A; Ileana E; Massard C; Albiges L; Di Palma M; Escudier B; Fizazi K
Eur J Cancer; 2015 Sep; 51(14):1946-52. PubMed ID: 26208462
[TBL] [Abstract][Full Text] [Related]
10. Targeting the androgen receptor signaling pathway in advanced prostate cancer.
Chung C; Abboud K
Am J Health Syst Pharm; 2022 Jul; 79(15):1224-1235. PubMed ID: 35390118
[TBL] [Abstract][Full Text] [Related]
11. Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance.
Crona DJ; Milowsky MI; Whang YE
Clin Pharmacol Ther; 2015 Dec; 98(6):582-9. PubMed ID: 26331358
[TBL] [Abstract][Full Text] [Related]
12. A novel nonsense mutation in androgen receptor confers resistance to CYP17 inhibitor treatment in prostate cancer.
Han D; Gao S; Valencia K; Owiredu J; Han W; de Waal E; Macoska JA; Cai C
Oncotarget; 2017 Jan; 8(4):6796-6808. PubMed ID: 28036278
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis.
Yuan X; Cai C; Chen S; Chen S; Yu Z; Balk SP
Oncogene; 2014 May; 33(22):2815-25. PubMed ID: 23752196
[TBL] [Abstract][Full Text] [Related]
14. ASC-J9(®) suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L.
Wang R; Lin W; Lin C; Li L; Sun Y; Chang C
Cancer Lett; 2016 Aug; 379(1):154-60. PubMed ID: 27233475
[TBL] [Abstract][Full Text] [Related]
15. Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.
Al Nakouzi N; Le Moulec S; Albigès L; Wang C; Beuzeboc P; Gross-Goupil M; de La Motte Rouge T; Guillot A; Gajda D; Massard C; Gleave M; Fizazi K; Loriot Y
Eur Urol; 2015 Aug; 68(2):228-35. PubMed ID: 24837187
[TBL] [Abstract][Full Text] [Related]
16. Androgen Receptor Rearrangement and Splicing Variants in Resistance to Endocrine Therapies in Prostate Cancer.
Ho Y; Dehm SM
Endocrinology; 2017 Jun; 158(6):1533-1542. PubMed ID: 28368512
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches.
Karantanos T; Corn PG; Thompson TC
Oncogene; 2013 Dec; 32(49):5501-11. PubMed ID: 23752182
[TBL] [Abstract][Full Text] [Related]
18. T-LAK cell-originated protein kinase (TOPK) enhances androgen receptor splice variant (ARv7) and drives androgen-independent growth in prostate cancer.
Alhawas L; Amin KS; Salla B; Banerjee PP
Carcinogenesis; 2021 Apr; 42(3):423-435. PubMed ID: 33185682
[TBL] [Abstract][Full Text] [Related]
19. Androgen deprivation of prostate cancer: Leading to a therapeutic dead end.
Katzenwadel A; Wolf P
Cancer Lett; 2015 Oct; 367(1):12-7. PubMed ID: 26185001
[TBL] [Abstract][Full Text] [Related]
20. Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy.
Cheng Q; Butler W; Zhou Y; Zhang H; Tang L; Perkinson K; Chen X; Jiang XS; McCall SJ; Inman BA; Huang J
Eur Urol; 2022 May; 81(5):446-455. PubMed ID: 35058087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]